[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"relapsedrefractory-large-b-cell-lymphoma-lbcl\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:relapsedrefractory-large-b-cell-lymphoma-lbcl":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100640480","phase-2-rimegepant-plus-glofitamab-and-cd19-car-t-therapy-in-rr-lbcl-100640480",false,"NCT07613788","Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R\u002FR LBCL","A Study to Evaluate the Efficacy and Safety of Rimegepant Plus Glofitamab and CD19 CAR-T Cell Therapy in Patients With High-Risk Relapsed\u002FRefractory Large B-Cell Lymphoma","Inclusion Criteria:\n\n* Able to understand and voluntarily sign the written informed consent form.\n* Age 18 years or older.\n* Histologically confirmed large B-cell lymphoma with CD19 and CD20 expression.\n* Relapsed or refractory disease after at least one prior line of systemic therapy.\n* Prior treatment must have included an anthracycline-containing chemotherapy regimen and an anti-CD20 monoclonal antibody.\n* Considered suitable by the investigator to receive glofitamab and CD19 CAR-T cell therapy.\n* Presence of at least one high-risk feature, including extranodal involvement, bulky disease, or TP53 abnormality.\n* ECOG performance status of 0 to 2.\n* Life expectancy of at least 12 weeks.\n* Adequate bone marrow, hepatic, renal, pulmonary, and cardiac function as determined by the investigator.\n* Participants of reproductive potential must agree to use effective contraception during the study period.\n* Able and willing to comply with the study protocol, in the investigator's judgment.\n\nExclusion Criteria:\n\n* History of hypersensitivity to any study treatment or related compounds.\n* Active or uncontrolled infection requiring systemic treatment.\n* History of allogeneic hematopoietic stem cell transplantation or organ transplantation.\n* Uncontrolled or clinically significant viral infection as defined by the protocol.\n* Known central nervous system involvement by lymphoma or clinically significant central nervous system disease that may interfere with study treatment or safety assessment.\n* Severe or uncontrolled cardiovascular disease.\n* Severe autoimmune disease or immune-mediated disease that may interfere with study treatment or safety assessment.\n* Known or suspected history of hemophagocytic lymphohistiocytosis.\n* Recent thromboembolic event before screening.\n* History of another malignancy within 5 years before screening, except adequately treated carcinoma in situ or non-melanoma skin cancer.\n* Receipt of prohibited anticancer therapy, immunosuppressive therapy, live attenuated vaccine, or other prohibited treatment within the protocol-specified period before enrollment.\n* Pregnant or breastfeeding women, or participants planning pregnancy during the study period.\n* Concurrent participation in another interventional clinical trial.\n* Need for prohibited concomitant medications that cannot be discontinued or substituted.\n* Any condition that, in the investigator's judgment, makes the participant unsuitable for study treatment or study participation.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study is designed to evaluate the efficacy and safety of rimegepant in combination with glofitamab and CD19 CAR-T cell therapy in patients with high-risk relapsed\u002Frefractory large B-cell lymphoma. Eligible patients will be randomized to receive glofitamab plus CD19 CAR-T cell therapy with or without rimegepant. The primary endpoint is complete response rate at 6 months after CAR-T cell infusion.",[26],"Relapsed\u002FRefractory Large B-cell Lymphoma (LBCL)","NOT_YET_RECRUITING","2026-05-23",{"date":30,"type":31},"2026-05-29","ACTUAL",{"date":33,"type":20},"2026-05",{"date":35,"type":20},"2029-04",{"name":37,"class":38},"Ruijin Hospital","OTHER"]